Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flotegatide
- Development stage
- Phase 2
- Lead developer
- Siemens
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
Flotegatide is a cyclic tripeptide containing an arginine-glycine-aspartic acid (R-G-D) motif. Its ^18F-radiolabeled form is used as a positron emission tomography (PET) tracer that selectively binds to integrin alpha-V/beta-3, a protein expressed by macrophages and neovascular endothelium. This allows for the imaging of processes such as inflammation, angiogenesis, and neovascularization in diseases like cancer and atherosclerosis. Flotegatide was developed primarily as a diagnostic radiopharmaceutical for visualizing tumors and vascular disease but has been discontinued in clinical development[1][3][4][5][7].
- Other names
- 1010702-99-41010702-75-6
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on flotegatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flotegatide.